U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
Commission
File Number: 000-21990
Notification
of Late Filing
(Check
One):
☐
Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR
For
Period Ended: September 30, 2025
| |
☐ |
Transition
Report on Form 10-K |
| |
☐ |
Transition
Report on Form 20-F |
| |
☐ |
Transition
Report on Form 11-K |
| |
☐ |
Transition
Report on Form 10-Q |
| |
☐ |
Transition
Report on Form N-SAR |
For
the Transition Period Ended:
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
Part
I - Registrant Information
Oncotelic
Therapeutics, Inc.
Full
Name of Registrant
Mateon
Therapeutics, Inc.
Former
Name if Applicable
29397
Agoura Road Suite 107
Address
of Principal Executive Office (Street and Number)
Agoura
Hills, CA 91301
City,
State and Zip Code
Part
II - Rules 12b-25(b) and (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-(b),
the following should be completed. (Check box, if appropriate)
☒
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form
N- SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed
due date; and
☒
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
Part
III - Narrative
State
below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof could not
be file within the prescribed period.
The
Company is working on and unable to compile the necessary financial information required to prepare a complete filing. Thus, the Company
would be unable to file the periodic report in a timely manner without unreasonable effort or expense. The Company expects to file within
the extension period.
Part
IV - Other Information
(1)
Name and telephone number of person to contract in regard to this notification.
| Amit
Shah |
|
(650) |
|
635-7000 |
| (Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2)
Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
☒
Yes ☐ No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No
If
so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Oncotelic
Therapeutics, Inc.
(Name
of Registrant as specified in charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
| Date:
November 14, 2025 |
By: |
/s/
Amit Shah |
| |
Amit Shah |
| |
Its: |
Chief Financial Officer |
